NCT05513014View on ClinicalTrials.gov

Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis

CompletedOBSERVATIONAL
Enrollment

1,518

Participants

Timeline

Start Date

March 21, 2021

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
Psoriasis
Interventions
DRUG

Secukinumab

Patients with Psoriasis who initiated Secukinumab

Trial Locations (1)

07936-1080

Novartis Pharmaceuticals, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY